Physician profile
Mark R Dosch
NPI 1144255530
$5,217.41
in general payments reported to CMS, 2019-2025
28 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $817 · 2021: $989 · 2022: $785 · 2023: $449 · 2024: $479 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,281.05 | 2019-2025 | Linzess, Creon, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $956.95 | 2019-2025 | Xifaxan, Trulance |
| Romark Laboratories, Lc | $427.91 | 2019-2020 | |
| Janssen Biotech, INC. | $280.71 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Redhill Biopharma INC. | $276.82 | 2020-2022 | |
| Gilead Sciences, INC. | $272.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $223.94 | 2019-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $202.24 | 2020-2024 | Entyvio |
| Madrigal Pharmaceuticals | $177.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $170.77 | 2021-2023 | |
| Vivus LLC | $140.94 | 2021-2025 | Qsymia, Pancreaze |
| Daiichi Sankyo INC. | $134.24 | 2019 | |
| Exact Sciences Corporation | $132.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $79.09 | 2025 | |
| Intercept Pharmaceuticals, INC. | $75.31 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $68.75 | 2023-2025 | Sucraid |
| Celgene Corporation | $62.18 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $38.54 | 2024 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $37.33 | 2024-2025 | Vowst |
| Concordia Pharmaceuticals INC. | $33.13 | 2019 | |
| Olympus America INC. | $30.41 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $22.20 | 2024 | Dat Device |
| Alnylam Pharmaceuticals INC. | $21.06 | 2022 | |
| Novo Nordisk INC | $16.13 | 2025 | Wegovy |
| Allergan, INC. | $15.95 | 2019 | |
| Glaxosmithkline, LLC. | $15.87 | 2021 | |
| Endo Pharmaceuticals INC. | $11.36 | 2021 | |
| Napo Pharmaceuticals INC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dosch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.